In addition, NF-κB/IL-6/STAT3 axis plays a key role in cancer chemotherapeutic resistance, where NF-κB can activate IL-6, which then can subsequently activate STAT3 through its receptor (Grivennikov and Karin, 2010). Here, NFKB1 is linked to cancer.